Newer Diabetes Drugs, Including GLP-1 Agonists, Tied to Autoimmunity Risk
Little previous research has examined immunological effects of newer antidiabetic agents including DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors. This study analyzed a large medical records database to look…
